Text Size

Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Tabriz University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Tabriz University
ClinicalTrials.gov Identifier:
NCT00602186
First received: April 18, 2007
Last updated: January 26, 2008
Last verified: January 2008
History of Changes

April 18, 2007
January 26, 2008
July 2005
March 2007   (final data collection date for primary outcome measure)
patient symptoms improvement(Standard questionare) [ Time Frame: every month untile 3 months ] [ Designated as safety issue: Yes ]
  • patient symptoms improvement(Standard questionare)and
  • Decrease post void residual urine
Complete list of historical versions of study NCT00602186 on ClinicalTrials.gov Archive Site
Urodynamics parameters improvement [ Time Frame: three months later ] [ Designated as safety issue: Yes ]
Urodynamics parameters improvement
Not Provided
Not Provided
 
Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction
Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)

Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Neurogenic Bladder
  • Drug: tamsolusin
    0.4 mg /day
    Other Name: Flomax
  • Drug: prazosin
    1 mg/day
  • Experimental: 1
    taking Tamsulosin
    Intervention: Drug: tamsolusin
  • Active Comparator: 2
    taking prasosin
    Intervention: Drug: prazosin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
80
March 2008
March 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy females with voiding difficulty with MFR<12 and post void residual urine>50cc

Exclusion Criteria:

  • History of pelvic floor surgury during last 3 month
  • Any contraindication for Tamsolusin or prazosin
Female
20 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00602186
85-1
Yes
Lily Nosraty, Tabriz University
Tabriz University
Not Provided
Study Director: SAKINEH hajebrahimi, MD Urology department ofTabriz University of Medical Sciences
Tabriz University
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP